197 related articles for article (PubMed ID: 26278893)
1. Is dasatinib-related pulmonary hypertension a clinical concern?
Szmit S
Future Oncol; 2015 Sep; 11(18):2491-4. PubMed ID: 26278893
[No Abstract] [Full Text] [Related]
2. Dasatinib-induced loss of eyebrows.
Naithani R
Br J Haematol; 2017 Nov; 179(3):362. PubMed ID: 28737227
[No Abstract] [Full Text] [Related]
3. Should vascular effects of newer treatments be addressed more completely?
Yang EH; Watson KE; Herrmann J
Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
[No Abstract] [Full Text] [Related]
4. Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.
Hong JH; Lee SE; Choi SY; Kim SH; Jang EJ; Bang JH; Park JE; Jeon HR; Oh YJ; Yi JE; Jung HO; Youn HJ; Kim DW
Cancer Res Treat; 2015 Oct; 47(4):937-42. PubMed ID: 25648097
[TBL] [Abstract][Full Text] [Related]
5. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
[TBL] [Abstract][Full Text] [Related]
6. Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?
Saydan B; Özmen D; Eşkazan AE
Expert Rev Hematol; 2024 Jul; 17(7):275-277. PubMed ID: 38888284
[No Abstract] [Full Text] [Related]
7. Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.
Cortes JE; Jimenez CA; Mauro MJ; Geyer A; Pinilla-Ibarz J; Smith BD
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):78-82. PubMed ID: 28082112
[TBL] [Abstract][Full Text] [Related]
8. [Pulmonary arterial hypertension and chronic heart failure as dasatinib cardiotoxicity. A case report].
Makeeva LM; Emelina EI; Gendlin GE; Nikitin IG; Vasyuk YA; Nesvetov VV
Kardiologiia; 2017 Apr; 57(S4):53-60. PubMed ID: 29466183
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report.
Kostos L; Burbury K; Srivastava G; Prince HM
Platelets; 2015; 26(8):809-11. PubMed ID: 26029798
[TBL] [Abstract][Full Text] [Related]
10. [Development of pulmonary arterial hypertension during oral dasatinib therapy for chronic myelogenous leukemia].
Morishita S; Hagihara M; Itabashi M; Ishii Y; Yamamoto W; Numata A; Motohashi K; Matsumoto K; Fujisawa S; Nakajima H
Rinsho Ketsueki; 2016 Aug; 57(8):999-1003. PubMed ID: 27599415
[TBL] [Abstract][Full Text] [Related]
11. [Reversible dasatinib-related pulmonary arterial hypertension in a CML patient].
Nagasaki J; Aoyama Y; Nomoto Y; Ido K; Ichihara H; Mugitani A
Rinsho Ketsueki; 2016 May; 57(5):618-23. PubMed ID: 27263788
[TBL] [Abstract][Full Text] [Related]
12. [Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
Edahiro Y; Takaku T; Konishi H; Tsukune Y; Fujioka I; Takasu K; Gotoh A; Daida H; Komatsu N
Rinsho Ketsueki; 2017; 58(11):2213-2218. PubMed ID: 29212971
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib-induced Pulmonary Hypertension.
Tamura Y; Tamura Y
Intern Med; 2022 Aug; 61(15):2245-2246. PubMed ID: 35110497
[No Abstract] [Full Text] [Related]
14. Pulmonary arterial hypertension in a patient treated with dasatinib: a case report.
Skride A; Sablinskis M; Sablinskis K; Lesina K; Lejnieks A; Lejniece S
J Med Case Rep; 2017 Dec; 11(1):362. PubMed ID: 29287600
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Shah NP; Wallis N; Farber HW; Mauro MJ; Wolf RA; Mattei D; Guha M; Rea D; Peacock A
Am J Hematol; 2015 Nov; 90(11):1060-4. PubMed ID: 26284693
[TBL] [Abstract][Full Text] [Related]
16. Hypopigmentation of the Skin and Hair Associated with Dasatinib Therapy.
Sharma V; Bagrodia V
Turk J Haematol; 2024 May; 41(2):116-117. PubMed ID: 37698254
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.
Ishida Y; Murai K; Yamaguchi K; Miyagishima T; Shindo M; Ogawa K; Nagashima T; Sato S; Watanabe R; Yamamoto S; Hirose T; Saitou S; Yonezumi M; Kondo T; Kato Y; Mochizuki N; Ohno K; Kishino S; Kubo K; Oyake T; Ito S;
Eur J Clin Pharmacol; 2016 Feb; 72(2):185-93. PubMed ID: 26507546
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
McGrath K; Stein B; Kalhagen L; Leighton L
Ann Allergy Asthma Immunol; 2017 Jul; 119(1):85-86. PubMed ID: 28499700
[No Abstract] [Full Text] [Related]
19. Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.
Latagliata R; Stagno F; Annunziata M; Abruzzese E; Iurlo A; Guarini A; Fava C; Gozzini A; Bonifacio M; Sorà F; Leonetti Crescenzi S; Bocchia M; Crugnola M; Castagnetti F; Capodanno I; Galimberti S; Feo C; Porrini R; Pregno P; Rizzo M; Antolino A; Mauro E; Sgherza N; Luciano L; Tiribelli M; Russo Rossi A; Trawinska M; Vigneri P; Breccia M; Rosti G; Alimena G
Neoplasia; 2016 Sep; 18(9):536-40. PubMed ID: 27659013
[TBL] [Abstract][Full Text] [Related]
20. Vascular events may predict the prognosis of patients with chronic myeloid leukemia.
Ureshino H; Kamachi K
Int J Hematol; 2020 Aug; 112(2):263. PubMed ID: 32533516
[No Abstract] [Full Text] [Related]
[Next] [New Search]
